Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Overall survival after immunotherapy, tyrosine kinase inhibitors and surgery in treatment of metastatic renal cell cancer: outcome of 143 consecutive patients from a single centre

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Robotic versus laparoscopic urological surgery: incidence of reoperation and complications

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Successful extraction of sperm cells after autologous bone marrow transplant: a case report

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The prognostic impact of incidental prostate cancer following radical cystoprostatectomy: a nationwide analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. National incidence and survival of patients with non-invasive papillary urothelial carcinoma: a Danish population study

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Implantation of the argus sling in a hard-to-treat patient group with urinary stress incontinence

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Community-based football in men with prostate cancer: 1-year follow-up on a pragmatic, multicentre randomised controlled trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Pattern of mortality after menopausal hormone therapy: long-term follow up in a population-based cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. National incidence and survival of patients with non-invasive papillary urothelial carcinoma: a Danish population study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Abstract Objective. The aim of this study was to evaluate overall survival (OS) after treatment of metastatic renal cell carcinoma (mRCC) following the introduction of tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors. Material and methods. One-hundred and forty-three consecutive mRCC patients were given immunotherapy (n = 59), TKIs (n = 49) or sequential therapy (IMM→TKI group; n = 35). The TKI group included patients with higher age (p < 0.001), worse performance status (p = 0.005) and higher risk profile (p < 0.001) than the other two treatment groups. Number of metastases and sites and tumour histology did not differ between groups. Results. First line immunotherapy gave a median OS of 16.3 months and first line TKIs 10.9 months (p = 0.003). Survival longer than 5 years was limited to immunotherapy. Sarcomatoid component, metastatic sites, papillary histology, stage, performance status and white cell blood count were related to poor OS. Using multivariate analyses to adjust for risk predictors the difference in OS disappeared. Median OS before and after introduction of TKIs was 16 months and 14 months, respectively (p = 0.189). Memorial Sloan Kettering Cancer Center (MSKCC) risk groups were related to OS (p < 0.001). Heng's prognostic criteria appeared slightly more predictive than MSKCC (p = 0.12). Metastasectomy (n = 42) may improve OS [surgery: median OS 18.8 months, 95% confidence interval (CI) 12.3-48.5; no surgery: median OS 15 months, 95% CI 10.4-16.5; p = 0.07]. Conclusions. MSKCC and Heng's prognostic algorithms were valid for prognostication and can be used for individual planning of treatment and follow-up. Surgical removal of metastases may improve OS.

Original languageEnglish
JournalScandinavian Journal of Urology
Volume48
Issue number4
Pages (from-to)379-86
ISSN0036-5599
DOIs
Publication statusPublished - 12 Feb 2014

ID: 44261384